This page shows the latest SMA Europe news and features for those working in and with pharma, biotech and healthcare.
SMA Europe deems access programme 'inappropriate'. Novartis has responded to criticism over its managed access programme for spinal muscular atrophy (SMA) gene therapy Zolgensma, with patient groups accusing the company of ... For SMA Europe, the fact
Biogen closed in on EU approval of its spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) in Europe, having already picked up a US approval for the highly-priced drug as 2016 ... Spinraza is the first drug for the rare and often fatal genetic
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....